TERT and neoplasm: Indeed, TERT-based ACT promoted a significant survival benefit (Figure 5C): in particular, in the case of mice engrafted with B-ALL#1 blasts, only the 16% of mice treated with hTERT-specific ACT developed, after 60 days from tumour challenge, an expansion of malignant human B cells that reached the threshold for sacrifice.